Ex vivo models have demonstrated the effectiveness of the joint inhibition of TIGIT and PD-1 in relation to the restoration of the functions of CD8+ T lymphocytes derived from the TILs population of hepatocellular carcinoma [130]. Here, PDCD1 is linked to hepatocellular carcinoma.